Biocept, Inc. Sustainability Profile
Biocept, Inc., a leading molecular diagnostics company headquartered in the United States, specialises in the development of innovative liquid biopsy technologies. Founded in 2011, Biocept has made significant strides in the oncology sector, focusing on the detection and monitoring of cancer through its proprietary assays. The company’s core offerings include its advanced circulating tumour cell (CTC) and circulating tumour DNA (ctDNA) tests, which provide critical insights for personalised cancer treatment. Biocept's unique approach to liquid biopsies sets it apart in the competitive landscape, enabling non-invasive testing that enhances patient care. With a strong market position, Biocept has achieved notable milestones, including partnerships with major healthcare institutions and a growing portfolio of intellectual property. As it continues to expand its operational reach, Biocept remains committed to advancing cancer diagnostics and improving patient outcomes.
DitchCarbon Score
How does Biocept, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biocept, Inc.'s score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biocept, Inc.'s reported carbon emissions
Biocept, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Biocept may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As such, the company does not inherit any emissions data from a parent organisation, nor does it participate in recognised climate frameworks like the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP).
How Carbon Intensive is Biocept, Inc.'s Industry?
How Carbon Intensive is Biocept, Inc.'s Location?
Biocept, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biocept, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
